跳至主要内容
临床试验/TCTR20171128005
TCTR20171128005已完成不适用

PREVALENCE SURVEY OF PLASMODIUM FALCIPARUM ANTIMALARIAL DRUG RESISTANCE MARKERS AT SITES IN INDIA

St. John Research Institute0 个研究点目标入组 400 人开始时间: 2017年11月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
400

研究概览

简要总结

The results indicate that artesunate + sulphadoxine-pyrimethamine, the artemisinin-based combination therapy (ACT) used as the first-line antimalarial treatment, is likely to be efficacious. However, there appears to be a high prevalence of the molecular markers seen in recrudescent parasites following treatment with lumefantrine. These results will be completed with testing for additional mutations in pfmdr1 and pfcrt genes known to be associated with such recrudescence.

研究设计

研究类型
Observational

入排标准

年龄范围
6 Months 至 75 Years(—)
性别
All

入选标准

  • Participants must meet all of the inclusion criteria to participate in the study.
  • -Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection
  • -Written informed consent obtained
  • All participants meeting inclusion criteria will have their dried blood spots retained for parasite molecular analyses.

排除标准

  • Patients presenting signs of severe malaria will be excluded from the survey to prevent any delay in the management of the patient.

研究者

相似试验